Ken Griffin
CCCC icon

Ken Griffin’s C4 Therapeutics CCCC Stock Holding History

Ken Griffin’s Portfolio CCCC Stock Details CCCC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$116K Buy
44,000
+31,900
+264% +$75.1K ﹤0.01% 11891
2025
Q4 		$23.1K Buy
+12,100
New +$28.7K ﹤0.01% 12308
2025
Q1 		– Sell
-25,700
Closed -$92.5K – 14552
2024
Q4 		$92.5K Sell
25,700
-59,400
-70% -$295K ﹤0.01% 11591
2024
Q3 		$485K Buy
85,100
+36,200
+74% +$218K ﹤0.01% 8324
2024
Q2 		$226K Sell
48,900
-4,700
-9% -$28K ﹤0.01% 9675
2024
Q1 		$438K Sell
53,600
-39,400
-42% -$305K ﹤0.01% 8675
2023
Q4 		$525K Buy
93,000
+84,400
+981% +$192K ﹤0.01% 7987
2023
Q3 		$16K Sell
8,600
-23,100
-73% -$70.5K ﹤0.01% 12793
2023
Q2 		$87.2K Buy
31,700
+2,300
+8% +$7.39K ﹤0.01% 11135
2023
Q1 		$92.3K Buy
29,400
+19,800
+206% +$117K ﹤0.01% 11378
2022
Q4 		$56.6K Sell
9,600
-6,000
-38% -$49.8K ﹤0.01% 11969
2022
Q3 		$137K Buy
15,600
+4,400
+39% +$45.7K ﹤0.01% 10808
2022
Q2 		$84K Sell
11,200
-9,300
-45% -$81.8K ﹤0.01% 11560
2022
Q1 		$497K Buy
20,500
+2,000
+11% +$48.6K ﹤0.01% 9413
2021
Q4 		$596K Buy
18,500
+11,400
+161% +$451K ﹤0.01% 9238
2021
Q3 		$317K Sell
7,100
-14,600
-67% -$625K ﹤0.01% 10948
2021
Q2 		$821K Buy
+21,700
New +$777K ﹤0.01% 8875

Other funds holding CCCC

Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
LCM
Lynx1 Capital Management San Juan, Puerto Rico $633M AUM 173.22% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Ken Griffin's CCCC Position: Q1 2026 in Review

Ken Griffin increased its C4 Therapeutics (CCCC) stake by 461% in Q1 2026, buying an estimated $4.86M and bringing the position to 2,511,015 shares worth $6.6M. The position accounts for ﹤0.01% of the portfolio, ranked #3893.

Ken Griffin first reported a position in CCCC in Q4 2020 and has held it in 20 quarters since. 123 funds tracked by Wall St. Rank hold CCCC as of Q1 2026.

  • Ken Griffin held 2,511,015 shares of C4 Therapeutics worth $6.6M as of Q1 2026.
  • Ken Griffin bought 2,063,207 C4 Therapeutics shares in Q1 2026, an estimated $4.86M.
  • C4 Therapeutics made up ﹤0.01% of Ken Griffin's portfolio in Q1 2026, its #3893 holding.
  • Ken Griffin first reported a position in C4 Therapeutics in Q4 2020 and has held it in 20 quarters since.
  • 123 funds tracked by Wall St. Rank held C4 Therapeutics as of Q1 2026.

Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.